

ASPEN PUBLISHERS

Antitrust Law

Index and Tables Pamphlet

2009 Edition

Phillip E. Areeda
Herbert Hovenkamp

Volumes I-XIV

- Complete Table of Contents
- Table of Cases
- Index



Wolters Kluwer
Law & Business

A



IS

30806175

Antitrust Law

**Phillip E. Areeda
and
Herbert Hovenkamp**

with contributions from

Roger D. Blair (vol. IIA)

Christine Piette Durrance (vol. IIA)

Einer Elhauge (vol. X)


John L. Solow (vols. IIA, IV and IVA)

Donald F. Turner (vol. V)

Index and Tables Pamphlet

2009 Edition

1. Complete Table of Contents (vols. I-XIV)
2. Table of Cases (vols. I-XIV)
3. Index (vols. I-XIV)



Wolters Kluwer

Law & Business

AUSTIN BOSTON CHICAGO NEW YORK THE NETHERLANDS

This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold with the understanding that the publisher is not engaged in rendering legal, accounting, or other professional services. If legal advice or other professional assistance is required, the services of a competent professional person should be sought.

—From a *Declaration of Principles* jointly adopted
by a Committee of the American Bar Association
and a Committee of Publishers and Associations

© 2008 Aspen Publishers. All Rights Reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording or any information storage and retrieval system, without permission in writing from the publisher. Requests for permission to reproduce content should be directed to the Aspen Publishers website at www.aspenpublishers.com, or a letter of intent should be faxed to the permissions department at 212-771-0803.

Printed in the United States of America

1 2 3 4 5 6 7 8 9 0

Library of Congress Control Number: 2006930321

ISBN 978-0-7355-6428-2 (Set)

978-0-7355-7604-9 (Index and Tables Pamphlet)

About Wolters Kluwer Law & Business

Wolters Kluwer Law & Business is a leading provider of research information and workflow solutions in key specialty areas. The strengths of the individual brands of Aspen Publishers, CCH, Kluwer Law International and Loislaw are aligned within Wolters Kluwer Law & Business to provide comprehensive, in-depth solutions and expert-authored content for the legal, professional and education markets.

CCH was founded in 1913 and has served more than four generations of business professionals and their clients. The CCH products in the Wolters Kluwer Law & Business group are highly regarded electronic and print resources for legal, securities, antitrust and trade regulation, government contracting, banking, pension, payroll, employment and labor, and healthcare reimbursement and compliance professionals.

Aspen Publishers is a leading information provider for attorneys, business professionals and law students. Written by preeminent authorities, Aspen products offer analytical and practical information in a range of specialty practice areas from securities law and intellectual property to mergers and acquisitions and pension/benefits. Aspen's trusted legal education resources provide professors and students with high-quality, up-to-date and effective resources for successful instruction and study in all areas of the law.

Kluwer Law International supplies the global business community with comprehensive English-language international legal information. Legal practitioners, corporate counsel and business executives around the world rely on the Kluwer Law International journals, loose-leafs, books and electronic products for authoritative information in many areas of international legal practice.

Loislaw is a premier provider of digitized legal content to small law firm practitioners of various specializations. Loislaw provides attorneys with the ability to quickly and efficiently find the necessary legal information they need, when and where they need it, by facilitating access to primary law as well as state-specific law, records, forms and treatises.

Wolters Kluwer Law & Business, a unit of Wolters Kluwer, is headquartered in New York and Riverwoods, Illinois. Wolters Kluwer is a leading multinational publisher and information services company.

ASPEN PUBLISHERS SUBSCRIPTION NOTICE

This Aspen Publishers product is updated on a periodic basis with supplements to reflect important changes in the subject matter. If you purchased this product directly from Aspen Publishers, we have already recorded your subscription for the update service.

If, however, you purchased this product from a bookstore and wish to receive future updates and revised or related volumes billed separately with a 30-day examination review, please contact our Customer Service Department at 1-800-234-1660 or send your name, company name (if applicable), address, and the title of the product to:

ASPEN PUBLISHERS
7201 McKinney Circle
Frederick, MD 21704

Important Aspen Publishers Contact Information

- To order any Aspen Publishers title, go to *www.aspenpublishers.com* or call 1-800-638-8437.
- To reinstate your manual update service, call 1-800-638-8437.
- To contact Customer Care, e-mail *customer.care@aspenpublishers.com*, call 1-800-234-1660, fax 1-800-901-9075, or mail correspondence to Order Department, Aspen Publishers, PO Box 990, Frederick, MD 21705.
- To review your account history or pay an invoice online, visit *www.aspenpublishers.com/payinvoices*.



Wolters Kluwer
Law & Business

Table of Contents for Volumes I-XIV

VOLUME I (3d ed.)

PART ONE

Preliminary and Pervasive Issues: Antitrust Goals, Coverage, Procedure, and Economics

CHAPTER 1. The Objectives of Antitrust Law 3

- 100. Appropriate and Inappropriate Antitrust Objectives 3
 - a. Introduction 3
 - b. "Populist" goals vaguely consistent, but specific concerns and applications often inconsistent 4
 - c. Antitrust not designed to fix defects in governmental policy or failures in political markets 7

1A. Economic Concerns Dominate Historical Development of Competition Policy 8

- 101. Legal, Political, and Economic Background of Sherman Act: General Conclusions 8
- 102. Earliest "Anti-Trust" Policy in State Corporate Law 11
 - a. Introduction 11
 - b. Alternative legal approaches to "trusts" 15
 - c. Early legal models of the business "trust" 20
 - 1. Stock-transfer trust 21
 - 2. The asset-transfer combination 24
 - 3. The holding company 28
 - d. Failure of corporate law model 34
- 103. The Sherman Act: Intent of the Framers 41
 - a. Concern about monopoly prices or other injury; economic efficiency 42

- b. Concern with competitor injuries 49
 - c. General conclusions 52
 - 1. Failure to distinguish competitor and consumer injury 52
 - 2. External history indicates strong concern with injury to competitors 53
 - 3. Little enthusiasm for consumer lawsuits 56
 - d. Policy significance 59
 - 1. Sherman Act legislative history generally not decisive 59
 - 2. Legislative history of later antitrust statutes offers little more guidance 61
- 104. The Common Law, Economics, and the Evolution of Antitrust 63
 - a. Sherman Act went beyond common law 64
 - b. New approach included revised concepts of “coercion,” intent, and market power 79
 - c. Common law exception for articles of “prime necessity” rejected 85
 - d. *Addyston Pipe* misrepresented common law 90
 - e. Broad application of Sherman Act constitutional notwithstanding liberty of contract 94
 - f. Conclusion 97

1B. Economic Concerns Trump Inconsistent Policy Concerns 98

- 110. Governing Principles Summarized 98
- 111. Noneconomic Antitrust Goals Incoherent and Indefensible 100
 - a. Introduction: noneconomic goals give unacceptable results if consistently followed 100
 - b. Indeterminate position of interest groups 102
 - c. Consumers are only “universal” interest group 105
 - d. “Fairness” 106
 - e. “Populist” goals 107
 - 1. Generally 107

| | | |
|------|--|-----|
| 2. | Many populist goals are consistent with efficiency concerns | 108 |
| 3. | Goals inconsistent with efficiency may not be “populist” at all | 110 |
| 4. | Truly “populist” antitrust policy would be futile | 110 |
| 5. | Promoting populist goals at efficiency’s expense imposes unacceptable burdens on the courts | 112 |
| 6. | Populist goals are inappropriate as antitrust standards even if there is no conflict with efficiency | 114 |
| f. | Antitrust is badly designed to achieve most noneconomic or macroeconomic goals | 115 |
| 1. | Income distribution | 115 |
| 2. | Macroeconomic goals | 118 |
| 112. | Exclusively Economic Approach Coherent but Imperfect | 120 |
| a. | Introduction and summary | 120 |
| b. | Economic approach significantly more coherent than alternatives | 121 |
| 1. | Neoclassical economic model claims significant assent | 121 |
| 2. | Economic concerns dominate in most of the case law | 123 |
| 3. | Antitrust operates within parameters set by other public policies; “laissez faire” inapt | 127 |
| c. | Significant limitations on economic approach | 129 |
| 1. | Fidelity to statutes and the Constitution | 129 |
| 2. | Limits of economic analysis | 131 |
| 3. | Institutional limitations; appropriate response | 132 |
| 4. | Allocation of enforcement resources | 133 |
| d. | Nature and limitations of particular economic theory that is chosen | 135 |
| 113. | Economics Limits Role of Intent | 140 |

CHAPTER 2. The Domain of the Antitrust Laws: Jurisdiction, Immunities and Exclusions From Coverage 145

200. Regulatory Immunities and Exemptions;
General Principle Stated 146

2A. "Political Action" and Petitions to the Government 151

201. Introduction and Summary; *Noerr* and *Pennington* Decisions 151
- a. General conclusions summarized 151
 - b. *Noerr* 154
 - c. *Pennington* 159
202. Anticompetitive Purpose and Burden on Rivals or Rivalry Not Intrinsically Wrongful; Causation 161
- a. Generally 161
 - b. Validation by legislation, judicial decision, or authorized administrative action 165
 - c. Anticompetitive consequences of successful petition not "caused" by private act; boycotts against government distinguished 166
 - d. No antitrust remedy for burden on rivals incidental to good faith petitioning 170
203. Influencing Government Action by Improper or Unnecessarily Harmful Means 171
- a. Introduction; "sham" distinguished 171
 - b. Other remedies available 173
 - c. Loss of immunity does not entail antitrust violation 173
 - d. *Noerr* rationale 174
 - e. General criteria of impropriety — false or misleading information, bribery, other corruption 175
 - 1. Generally 175
 - 2. Bribery and explicit corruption 179
 - 3. Hard bargaining and threats 180
 - f. False and misleading information; legislative versus adjudicative context 182
 - 1. Only known falsity 183
 - 2. Arguments and "legislative" facts; lack of candor 184
 - 3. Materiality to government decision 185

| | |
|---|------------|
| 4. Directly burdening the plaintiff | 188 |
| 5. Factual misrepresentation to policymaking agency; <i>Unocal</i> decision | 189 |
| 6. Conclusion | 199 |
| g. Conspiracy with government official | 199 |
| 1. Anticompetitive official decisions, erroneous or not | 199 |
| 2. Supreme Court rejects most antitrust liability for corrupt or bad faith government decisions | 200 |
| 3. Personal interest | 202 |
| 4. Settlements of judicial disputes | 203 |
| 5. Policy bias | 207 |
| 6. Proving antitrust violation based on corruption or bad faith | 208 |
| 7. Pleadings and summary judgment | 211 |
| 8. Co-conspirator "exception" in the cases | 211 |
| 9. <i>Noerr</i> exception for conspiracies with the government: summary | 214 |
| h. Causation problem | 215 |
| i. Concerted political activity; market effects | 217 |
| j. General conclusions | 220 |
| 1. Legislative context | 220 |
| 2. Government decision making other than legislation | 221 |
| 2A-1. "Sham" Petitioning | 221 |
| 204. "Sham" or Bad Faith Action | 221 |
| a. <i>Noerr</i> principle; "sham" exception | 221 |
| b. "Sham" in legislative or rule-making context | 225 |
| c. "Sham" in adjudication and quasi-adjudication | 227 |
| d. "Access denying" | 235 |
| e. Lower court decisions defining "sham" | 237 |
| f. Conclusion | 238 |
| 205. Judicial and quasi-judicial petitions: "sham" and False Claims | 239 |
| a. Introduction | 239 |
| 1. Conclusions summarized | 239 |

| | | |
|------|--|-----|
| 2. | Objective test — legal theory versus fact | 241 |
| b. | <i>Professional Real Estate (PRE)</i> decision | 244 |
| c. | Successful claims | 254 |
| 1. | Generally | 254 |
| 2. | False information produces successful judicial or quasi-judicial claim | 258 |
| d. | Pending, unsuccessful, or novel claims | 260 |
| 1. | Generally | 260 |
| 2. | Substantive criteria of baselessness | 261 |
| 3. | Lack of standing; financial support | 263 |
| 4. | Unreasonable defensive conduct | 265 |
| e. | Repetitive lawsuits or agency filings | 267 |
| 1. | Single claim not inherently immune | 267 |
| 2. | Multiple actions in one or multiple forums | 268 |
| f. | Unlitigated disputes; threats to sue and collateral communications and filings | 277 |
| g. | Settlements | 282 |
| h. | Remedies for sham lawsuits | 285 |
| 206. | Requests for Government Actions That Are Unconstitutional, Unauthorized, or Otherwise Improper | 286 |
| a. | Petitioning not at peril | 286 |
| b. | Legislative or other action “Known” to be improper | 288 |
| c. | Federal determination of state law questions | 290 |
| 207. | Pleading and Proving Sham | 292 |
| a. | Problem stated | 292 |
| b. | Heightened pleading or proof burdens | 293 |
| c. | Fact or law; burden of proof | 298 |
| d. | Summary judgment before or after discovery | 300 |
| 208. | Sham as Antitrust Violation | 301 |

2A-2. Non-Immunity Outside of “Sham”; Collateral Issues 305

| | | |
|------|---|-----|
| 209. | “Commercial Exception”: Government as Buyer, Seller, Lessor, Lessee, Franchisor | 305 |
| a. | General rule | 305 |

| | |
|--|---------|
| b. Cartel engaged in price fixing or concerted refusal against government buyer | 307 |
| c. Unilateral seller action; government as buyer or as plaintiff | 309 |
| d. Restrictive purchase agreements | 311 |
| e. Government lessor or franchisor | 313 |
| 1. Summary | 313 |
| 2. Government victimized | 314 |
| 3. Government chooses monopoly | 314 |
| 4. Improper means | 316 |
| 210. Compulsory Filings with Government Agencies | 316 |
| a. Basic issue | 316 |
| b. Decisions divided, with most rejecting immunity | 319 |
| 1. Generally | 319 |
| 2. "Orange Book" filings of pharmaceutical patent extensions | 322 |
| 211. Petitions to Nongovernmental Bodies | 323 |
| 212. Evidentiary Use of Protected Activities; Discovery of "Sham" Litigation Documents | 332 |
| 2B. Antitrust in a Federal System: Relationship with State Regulation | 337 |
| 215. Introduction; Collateral Concerns of Federalism | 337 |
| a. Scope of this Subchapter | 337 |
| b. Other federalism concerns: Tenth and Eleventh Amendments | 340 |
| 2B-1. General Interplay of State Law and Federal Antitrust Law | 343 |
| 216. Concurrent Authority: Overlapping State and Federal Antitrust Laws | 343 |
| a. Introduction; no federal "intent" to displace state antitrust law generally | 343 |
| b. State law applications affecting interstate commerce; extraterritoriality | 345 |
| c. Substantive reach exceeds that of federal law | 345 |

- 217. Concerns for Competition and Federal Preemption of State or Local Regulation 351
 - a. Introduction; general definition of preemption problem 351
 - b. Explicit antitrust preemption decisions focus on unsupervised private power to violate antitrust laws 356
 - 1. *Midcal* 356
 - 2. *Rice* 358
 - 3. *Fisher*; “hybrid” restraint defined 362
 - 4. *324 Liquor*; “hybrid” restraint found 365
 - 5. *California* 367
 - c. Federal antitrust preemption of acts of local government 367
 - d. Relationship between basic preemption inquiry and *Parker* “state action” exemption 370
 - e. Note on the 1996 Telecommunications Act: federal preemption of state and local restraints on telecommunications competition 374

VOLUME IA (3d ed.)

2B-2. Areas of Federally Created Express Primacy for State Law 3

- 218. Express Federal Deference Generally 3
- 219. Federal antitrust Immunity for the “Business of Insurance” 4
 - a. Introduction 4
 - b. “Business of insurance” 5
 - 1. Generally; insurer agreements with providers of goods or services 5
 - 2. Peer review 12
 - 3. Non-physician limitations 13
 - 4. “Business of insurance” generally embraces insurer decisions concerning scope of policy; complementary services 14
 - 5. Insurer agreements with agencies and agents 21
 - 6. Horizontal agreements 21

| | |
|--|-----------|
| c. "Regulated by state law" — insurance immunity and <i>Parker</i> immunity compared | 24 |
| d. Implications of possible McCarran-Ferguson Act repeal | 29 |
| 220. Insurance Immunity: "Boycott" Exception | 31 |
| a. Concerted action | 32 |
| b. Meaning of "boycott" | 32 |
| 2B-3. Implied Antitrust Immunity for "State Action" | 42 |
| 221. Introduction: the Meaning of <i>Parker v. Brown</i> | 42 |
| a. Overview | 42 |
| b. <i>Parker</i> | 45 |
| c. Scope of original <i>Parker</i> immunity | 48 |
| d. Scope of <i>Parker</i> immunity: development of "authorization" requirement | 50 |
| 1. Meaning and necessity of authorization requirement | 50 |
| 2. Pre- <i>Midcal</i> decisions developing authorization requirement | 53 |
| 3. Determining intent: meaning of participation or approval | 55 |
| 4. Approval by subordinate state agencies | 56 |
| 5. Agency inaction | 60 |
| 6. Scope of agency authority; two-level intent inquiry | 60 |
| 7. Agency involved in proprietary activity | 61 |
| 8. Clear statement required | 62 |
| e. Scope of <i>Parker</i> immunity: development of "active supervision" requirement | 63 |
| 1. Introduction | 63 |
| 2. Decision by disinterested government official | 65 |
| 3. Bias and inattentiveness | 65 |
| 4. Self-executing statutes; conduct not requiring supervision | 66 |
| 5. Whose initiative? | 67 |
| 6. Agency inaction; presumption against adequacy of supervision | 67 |

- f. *Midcal* decision restates *Parker* requirements 69
 - g. Limitations on *Parker*: extraterritorial effects and other spillovers 70
- 222. Scope of *Parker* Immunity Outlined; Summary Disposition of *Parker* Claims 71
 - a. *Parker* outlined 71
 - b. Summary disposition of claims implicating *Parker* 77
- 223. Antitrust Liability for Governmental Subdivisions; Corrective Legislation 79
 - a. Introduction 79
 - b. *Lafayette* 81
 - c. Home rule municipalities; *Boulder* 84
 - d. Local Government Antitrust Act 89
- 224. State Authorization to Displace Antitrust Law 93
 - a. Introduction; complex *Parker* analysis often camouflages lack of any antitrust violation 93
 - b. Distinguishing “state itself” from subordinate agencies requiring authorization from above 96
 - 1. Basic principle 96
 - 2. Conflicting judicial approaches 97
 - c. Authorization does not require compulsion 103
 - 1. Weighty policy considerations disfavor compulsion requirement 103
 - 2. Compulsion as evidence of state purpose or supervision 107
 - 3. Compulsion neither necessary nor sufficient: *Hallie* and *Southern Motor* 108
 - d. Official errors or bad faith in carrying out authorized activities; “conspiracy” 112
 - 1. Problem stated 112
 - 2. Unauthorized “conspiracy” with government official 113
 - 3. *Columbia* decision rejects “conspiracy” claims 117
 - 4. Trend toward refusal to deny immunity to erroneous official decisions 123

| | | |
|------|---|-----|
| 5. | Deferral to state administrative and appellate remedies | 125 |
| e. | Non-authorization for proprietary activities? | 126 |
| 1. | Conclusions stated | 126 |
| 2. | Substantive antitrust law disposes of most cases involving proprietary activities | 127 |
| 3. | Properly authorized commercial activities immune | 128 |
| 225. | Ambiguities in Authorizing Provision | 131 |
| a. | Introduction; two meanings of "authorization" | 131 |
| b. | How precise must the state's "authorization" be? | 137 |
| 1. | <i>Hallie</i> decision | 139 |
| 2. | <i>Southern Motor</i> decision | 141 |
| 3. | "Foreseeability" of anticompetitive regulation | 144 |
| 4. | Ordinary corporate powers do not contemplate antitrust violation | 151 |
| 5. | Objective "foreseeability" contemplates economic reasonableness | 154 |
| 6. | Objective foreseeability: actions contrary to state's own public interest | 159 |
| c. | State judicial decision as authorization | 160 |
| 1. | State court decisions interpreting ambiguous or silent authorizing statute | 160 |
| 2. | State court decisions as creating authorization | 161 |
| d. | Retroactive authorization | 162 |
| 226. | Active Supervision Requirement: Domain and Nature | 163 |
| a. | Introduction | 163 |
| b. | Municipalities and the government's "public" agencies require no supervision | 164 |
| c. | Adequacy of supervision: the <i>Patrick</i> and <i>Ticor</i> decisions | 166 |
| 1. | <i>Patrick</i> and peer review | 166 |
| 2. | Oversight by state regulatory agencies and boards | 171 |

- d. Who must supervise? 192
 - e. Conduct not requiring supervision 194
- 227. The Need for Supervision: Identifying and Classifying the Relevant Actor 197
 - a. Introduction; problem stated 197
 - b. Recommendations 208
- 228. Non-Immunity But No Antitrust Violation of Penalty 209
 - a. Introduction 209
 - b. No antitrust violation 210
 - 1. No violation even for private firm 210
 - 2. "Reasonable" government regulation 213
 - c. Non-immunity and possible violation, but no punitive sanction — government defendants 214
 - 1. Generally 214
 - 2. Damages liability for state agencies or employees 220
 - d. Non-immunity of private defendants 222
 - 1. Introduction and summary 222
 - 2. Relevant interests 224
 - 3. Reasonable reliance; apparent authority 225
 - 4. State compulsion revisited 227
- 229. Relationship of *Noerr* and *Parker* Immunities 227
- 230. Possible Alternative Criteria for *Parker* Immunity 234
 - a. Introduction and summary 234
 - b. Approaches focusing on failure in political markets; special interests; extraterritoriality 237
 - c. Rule of reason approach 241
 - d. Objective foreseeability test implicates reasonableness and public interest 242
- 231. The "State Action" Doctrine in the Federal Trade Commission 243
 - a. Introduction 243
 - b. Greater Preemptive Reach of FTC Act? 244
 - 1. Arguments favoring greater preemptive reach 244